FLT3 Antikörper (APC)

Produktnummer ABIN1302621

Produktdetails anti-FLT3 Antikörper (APC)

Target: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FLT3 Antikörper ist konjugiert mit APC

Applikation: Flow Cytometry (FACS)

Verwendungszweck: Anti-Hu CD135 APC

Spezifität: The mouse monoclonal antibody BV10A4 (BV10) reacts with an extracellular epitope of CD135 (FLT3, FLK2, STK-1), a 130-160 kDa type I transmembrane receptor tyrosine kinase that is involved in early steps of hematopoiesis.

Keine Kreuzreaktivität: Maus

Kreuzreaktivität (Details): Human

Aufreinigung: Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: BV-173 leukemic cell line

Klon: BV10A4

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Details zu FLT3

Target: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Andere Bezeichnung: CD135 (FLT3 Produkte)

Hintergrund: Fms related tyrosine kinase 3,CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.,FLT3, FLK2, STK1

Gen-ID: 2322

UniProt: P36888

Pathways: RTK Signalweg